Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase III Study Evaluating Palbociclib (PD-0332991), a Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor in Patients With Hormone-receptor-positive, HER2-normal Primary Breast Cancer With High Relapse Risk After Neoadjuvant Chemotherapy "PENELOPEB"

Next Previous
X
Search
Trial Profile

Phase III Study Evaluating Palbociclib (PD-0332991), a Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor in Patients With Hormone-receptor-positive, HER2-normal Primary Breast Cancer With High Relapse Risk After Neoadjuvant Chemotherapy "PENELOPEB"

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 27 Nov 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Palbociclib (Primary) ; Gonadotropin releasing hormone stimulants; Tamoxifen
  • Indications Carcinoma; Early breast cancer; HER2 negative breast cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms PENELOPE-B

    • Most Recent Events

    • 26 Nov 2024 According to Biovica International media release, Biomarker analysis data from this study will be presented at San Antonio Breast Cancer Symposium (SABCS) on December 10-13, 2024.
    • 04 Jun 2024 Results assessing Relationship of adaptive subtyping and tumour heterogeneity of treatment response to neoadjuvant therapy in hormone receptor positive HER2-negative early breast cancer presented at the 60th Annual Meeting of the American Society of Clinical Oncology
    • 05 Nov 2023 Results of Patient-reported outcomes in high-risk HR+ /HER2- early breast cancer patients treated with endocrine therapy with or without palbociclib within this study, published in the European Journal of Cancer

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top